Dynavax Technologies is a biopharmaceutical company based in Emeryville, California, specializing in vaccines and immuno-oncology therapeutics, including the HEPLISAV-B hepatitis B vaccine. The company is developing additional vaccines, including candidates for shingles and Tdap.
David Kroin sold 970,143 shares of DVAX on 22 August at $10.59 per share, worth a total of $10.3M. They now own 15,726,349 DVAX shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.